Adial Pharmaceuticals ADIL Q1 2026 Earnings NarrowerThanExpected Loss as Operational Progress Continues Immunovant Q1 2026 Earnings Wider Than Expected Loss Amid No Revenue PEPG Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline ORCL Q1 2026 Earnings EPS Beats Estimates Stock Edges Higher GLBS Q4 2025 Earnings Strong EPS Surprise Driven by Operational Efficiency JAGX Q1 2026 Earnings Significant EPS Miss Highlights Operational Challenges